- Conditions
- Neoplasms
- Interventions
- BI 907828
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 9
- States / cities
- Santa Monica, California • New Haven, Connecticut • Sarasota, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 868
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Renal Cell Carcinoma
- Interventions
- Avelumab, Cabozantinib
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- CNS Lesion, Blood Brain Barrier Defect
- Interventions
- P03277, Gadobenate dimeglumine, MRI
- Drug · Device
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Farmington Hills, Michigan + 6 more
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
- Interventions
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo
- Biological · Other
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome
- Interventions
- Panobinostat, Cytarabine, Daunorubicin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- RSV vaccine formulation 1, RSV vaccine formulation 2, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 18 Months
- Enrollment
- 259 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 25
- States / cities
- Gardena, California • La Mesa, California • Los Angeles, California + 21 more
- Conditions
- Moderate to Severe Allergic Asthma
- Interventions
- CYT003, Placebo
- Biological
- Lead sponsor
- Cytos Biotechnology AG
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 21
- States / cities
- Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more
- Conditions
- Advanced Solid Tumors
- Interventions
- U3-1287 (AMG888)
- Drug
- Lead sponsor
- U3 Pharma GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more
- Conditions
- Breast Neoplasms, Breast Cancer
- Interventions
- Patritumab deruxtecan, Trastuzumab, Trastuzumab Biosimilar, Pertuzumab, Tucatinib
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New Brunswick, New Jersey + 2 more
- Conditions
- Osteoporosis
- Interventions
- teriparatide, Placebo, BA058 20 µg, BA058 40 µg, BA058 80 µg
- Drug
- Lead sponsor
- Radius Health, Inc.
- Industry
- Eligibility
- 55 Years to 85 Years · Female only
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Non-Small Cell Lunch Cancer
- Interventions
- Buparlisib, Buparlisib placebo, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas • Portland, Oregon
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
- Interventions
- ALXN2050, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Huntsville, Alabama • Loma Linda, California • Northridge, California + 7 more
- Conditions
- Adeno-Associated Virus (AAV), Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, Factor VIII (FVIII), Factor VIII (FVIII) Deficiency, Factor VIII (FVIII) Gene, Factor VIII (FVIII) Protein, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, Gene Therapy, Gene Transfer, Hematologic Diseases, Hemorrhagic Disorders, Recombinant, Vector, Inhibitors
- Interventions
- SPK-8016
- Genetic
- Lead sponsor
- Spark Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Peoria, Illinois • Ann Arbor, Michigan + 7 more
- Conditions
- Pneumococcal Vaccines
- Interventions
- 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,015 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 25
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Hollywood, Florida + 22 more
- Conditions
- Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
- Interventions
- EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant, Exemestane
- Drug
- Lead sponsor
- Ellipses Pharma
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 4 more
- Conditions
- Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, SCD1 Inhibitor MTI-301
- Procedure · Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Infections, Urinary Tract
- Interventions
- GSK2251052, imipenem-cilastatin, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Council Bluffs, Iowa • Topeka, Kansas + 1 more
- Conditions
- Depressive Disorder, Major
- Interventions
- 5 mg BI 1569912, Placebo matching BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 35
- States / cities
- Bellflower, California • Long Beach, California • Oceanside, California + 31 more
- Conditions
- Advanced Solid Tumors, Non-small Cell Lung Cancer
- Interventions
- BAY2862789
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Celebration, Florida • Detroit, Michigan • San Antonio, Texas
- Conditions
- Hypercholesteremia
- Interventions
- Gemcabene
- Drug
- Lead sponsor
- NeuroBo Pharmaceuticals Inc.
- Industry
- Eligibility
- 17 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Beverly Hills, California
- Conditions
- HIV Infections
- Interventions
- Zidovudine, Zalcitabine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- San Diego, California • Miami, Florida
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- carmoterol (CHF 4226), placebo, salmeterol
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 15
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
- Conditions
- Leukemia, Myeloid
- Interventions
- CC-96191
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Jacksonville, Florida • Atlanta, Georgia + 5 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- NNC0519-0130, Placebo, Trizepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 55
- States / cities
- Chula Vista, California • Fresno, California • Inglewood, California + 46 more